Kandemir, E. G.Mayadağlı, A.Yaylacı, M.Öztürk, A.2024-07-122024-07-122005Kandemir, E. G., Mayadagli, A., Turken, O., Yaylaci, M., & Ozturk, A. (2005). Pre-treatment haemoglobin concentration is a prognostic factor in patients with early-stage breast cancer. The Journal of international medical research, Sage Journals. 33(3), 319–328.0300-06051473-2300https://journals.sagepub.com/doi/abs/10.1177/147323000503300307https://hdl.handle.net/20.500.12415/3823We investigated the prevalence of anaemia (haemoglobin concentration < 12 g/dl) in 336 women with early-stage breast cancer and its association with other known prognostic factors. The median follow-up period was 60.5 months (range 9-123 months). Seventy-nine women (23.5%) had a low pre-treatment haemoglobin concentration, but anaemia was not correlated with age, tumour size, nodal status, histological grade or hormone receptor status. Univariate analysis revealed that disease-free survival and overall survival were shorter in patients with anaemia at the time of diagnosis than in patients with normal haemoglobin concentrations. Anaemia remained a significant prognostic factor for disease-free survival and overall survival in the multivariate analysis (relative risk, 1.884 and 1.785, respectively). These results suggest that pre-treatment haemoglobin concentration is an independent prognostic factor in patients with early-stage breast cancer.enCC0 1.0 Universalinfo:eu-repo/semantics/openAccessBreast cancerAnaemiaHaemoglobin concentrationPrognostic factorsArticle3283Q331933